<div id="readability-page-1"><p>In a report released on May 8, Lisa Walter from RBC Capital reiterated a Hold rating on Apellis Pharmaceuticals, with a price target of <span id="expert-recommendation-target">$41.00</span>. The company’s shares closed last Friday at $41.03.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>According to TipRanks, Walter is a 3-star analyst with an average return of <span>2.6%</span> and a 52.63% success rate. Walter covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals, United Therapeutics, and Apellis Pharmaceuticals.</p> <p>Currently, the analyst consensus on Apellis Pharmaceuticals is a Hold with an average price target of $39.59.</p></div>

APLS

<p>RBC Capital's Lisa Walter has maintained a Hold rating on Apellis Pharmaceuticals (APLS) with a price target of $41.00, slightly below the current share price of $41.03. Walter, a 3-star analyst, has an average return of 2.6% and a 52.63% success rate. The consensus among analysts for Apellis is also a Hold, with an average price target of $39.59.</p>

Tip Ranks

Apellis Pharma

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

iShares Global Healthcare

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

VG Health

SPDR S&P Biotech

iShares US Pharma

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

ROYAL BANK OF CANADA

Rhythm Pharma

United Therap

RBC Capital Remains a Hold on Apellis Pharmaceuticals (APLS)